The open-label study evaluated the safety and tolerability, biological activity, blood biomarkers and preliminary efficacy of COYA 301 in 8 patients with Alzheimer’s disease (AD). The ...
Researchers at Tsukuba University have discovered that the increase in regulatory T (Treg) cells, which typically suppress immune responses, does not adequately control elderly-onset rheumatoid ...
Understanding how regulatory T cells (Tregs) develop and work is key to determining how they might be manipulated to encourage the destruction of cancer cells or prevent autoimmunity. Cell behavior is ...
Northwestern Medicine scientists have discovered a new mechanism that controls a specialized group of T-cells, known as regulatory T-cells, and may serve as potential therapeutic targets to treat ...
COYA 303 is an investigational biologic combination of COYA 301, Coya’s low-dose interleukin 2 (LD IL-2) and a GLP-1 receptor agonist (GLP-1RA), designed to deliver a multi-targeted immunomodulatory ...
3D rendering of the tumor microenvironment. The recipe for a general and long-lasting cancer treatment could involve regulatory T cells, a type of white blood cell. This is the first installment in a ...
Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics ...
BioWorld - Friday, December 19, 2025 Breaking News: Trump administration impacts continue to roil the life sciences sector See today's BioWorld Science Home » Targeting Stk4 alters Treg cell function ...
Leonardo Ferreira, Ph.D., left, and graduate student Russell Cochrane envision CAR Tregs being useful in cancer, type 1 diabetes and organ transplants. A new paper from MUSC Hollings Cancer Center ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results